Baird downgraded Frequency Therapeutics to Neutral from Outperform with a price target of 50c, down from $4. The all-stock merger transaction with Korro Bio expected to close in the fourth quarter of this year, the analyst tells investors in a research note. The firm downgraded Frequency ahead of the closure of the transaction.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on FREQ: